Amwill Health Care Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Amwill Health Care Ltd is ₹ 35.49 as of 05 May 15:30 . The P/E Ratio of Amwill Health Care Ltd changed from 12.9 on March 2025 to 12.9 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 years The Market Cap of Amwill Health Care Ltd changed from ₹ 138.22 crore on March 2025 to ₹ 138.22 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 years The revenue of Amwill Health Care Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The ebitda of Amwill Health Care Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The net profit of Amwill Health Care Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Amwill Health Care Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 years .

About Amwill Health Care Ltd

Amwill Health Care Limited was originally incorporated on August 21, 2017 under the name Amwill Health Care Private Limited', dated August 22, 2017 issued by the Deputy Registrar of Companies, Karnataka at Bangalore.
Further, Company was converted into a Public Limited Company and a fresh Certificate of Incorporation dated January 25, 2024 was issued by the Registrar of Companies, Karnataka at Bangalore with the change in name to Amwill Health Care Limited'. Amwill Health Care Ltd is a derma-cosmetic development company, associated with contract manufacturers, distributor and third party product development agencies, which has enabled in developing capabilities, in manufacturing, packaging and distribution.
The core focus of Company is on development of problem solving dermatological, cosmeceutical and aesthetical products, and therefore to direct all efforts towards product formulation and development, the Company has outsourced key functions such as manufacturing, prototype development and distribution to third parties, for effective management and execution.

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

FAQs for the comparison of Amwill Health Care Ltd and Astrazeneca Pharma India Ltd

Which company has a larger market capitalization, Amwill Health Care Ltd or Astrazeneca Pharma India Ltd?

Market cap of Amwill Health Care Ltd is 70 Cr while Market cap of Astrazeneca Pharma India Ltd is 20,116 Cr

What are the key factors driving the stock performance of Amwill Health Care Ltd and Astrazeneca Pharma India Ltd?

The stock performance of Amwill Health Care Ltd and Astrazeneca Pharma India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Amwill Health Care Ltd and Astrazeneca Pharma India Ltd?

As of May 5, 2026, the Amwill Health Care Ltd stock price is INR ₹35.0. On the other hand, Astrazeneca Pharma India Ltd stock price is INR ₹8046.55.

How do dividend payouts of Amwill Health Care Ltd and Astrazeneca Pharma India Ltd compare?

To compare the dividend payouts of Amwill Health Care Ltd and Astrazeneca Pharma India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.